David L. Cahall

1.7k total citations
21 papers, 1.1k citations indexed

About

David L. Cahall is a scholar working on Oncology, Orthopedics and Sports Medicine and Infectious Diseases. According to data from OpenAlex, David L. Cahall has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Orthopedics and Sports Medicine and 5 papers in Infectious Diseases. Recurrent topics in David L. Cahall's work include Bone health and treatments (7 papers), Bone health and osteoporosis research (5 papers) and Tuberculosis Research and Epidemiology (3 papers). David L. Cahall is often cited by papers focused on Bone health and treatments (7 papers), Bone health and osteoporosis research (5 papers) and Tuberculosis Research and Epidemiology (3 papers). David L. Cahall collaborates with scholars based in United States, France and United Kingdom. David L. Cahall's co-authors include Richard Eastell, Nelson B. Watts, Pierre D. Delmas, Larry D. Scott, Andreas Grauer, Harry K. Genant, Patrick Garnero, Bernard Vrijens, J. D. Ringe and Guy P. Youmans and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Gastroenterology.

In The Last Decade

David L. Cahall

21 papers receiving 1.0k citations

Peers

Countries citing papers authored by David L. Cahall

Since Specialization

Citations

This map shows the geographic impact of David L. Cahall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David L. Cahall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David L. Cahall more than expected).

Fields of papers citing papers by David L. Cahall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David L. Cahall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David L. Cahall. The network helps show where David L. Cahall may publish in the future.

Co-authorship network of co-authors of David L. Cahall

This figure shows the co-authorship network connecting the top 25 collaborators of David L. Cahall. A scholar is included among the top collaborators of David L. Cahall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David L. Cahall. David L. Cahall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study 2012 ·Bone ·Richard Eastell, Patrick Garnero, Christine Audebert, David L. Cahall	65
2	Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence 2011 ·Journal of Bone and Mineral Research ·Richard Eastell, Bernard Vrijens, David L. Cahall, J. D. Ringe, Patrick Garnero, Nelson B. Watts	68
3	The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES) 2010 ·Osteoporosis International ·Olivier Bruyère, John А. Kanis, (unknown), (unknown), Maria Luisa Brandi, Nansa Burlet, David L. Cahall, Arkadi Chines, J.-P. Devogelaer, W. Dere, Niti Goel, Nicola Hughes, (unknown), (unknown), Bruce Mitlak, D. Niese, René Rizzoli, Lucio C. Rovati, J.-Y. Reginster	7
4	Relationships between osteoporosis medication adherence, surrogate marker outcomes and non-vertebral fracture incidence 2010 ·Bone ·Richard Eastell, Bernard Vrijens, David L. Cahall, Christian Roux, J. D. Ringe, Patrick Garnero, Nelson B. Watts	2
5	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis 2008 ·Bone ·René Rizzoli, Nansa Burlet, David L. Cahall, Pierre D. Delmas, Erik Fink Eriksen, Dieter Felsenberg, John T. Grbic, Mats Jontell, Regina Landesberg, Andrea Laslop, (unknown), Socrates E. Papapoulos, Orhan Sezer, (unknown), Jean‐Yves Reginster	157
6	Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis 2007 ·The Journal of Clinical Endocrinology & Metabolism ·Pierre D. Delmas, Bernard Vrijens, Richard Eastell, Christian Roux, Huibert A. P. Pols, J. D. Ringe, Andreas Grauer, David L. Cahall, Nelson B. Watts, (unknown)	127
7	Impact of Osteonecrosis of the Jaw on Osteoporosis Management: Executive Summary of an ESCEO and Foundation for Research on Osteoporosis and Other Bone Diseases Working Group Meeting 2007 ·Aging Health ·René Rizzoli, Nansa Burlet, David L. Cahall, Pierre D. Delmas, Erik Fink Eriksen, Dieter Felsenberg, John T. Grbic, Mats Jontell, Regina Landesberg, Andrea Laslop, (unknown), Socrates E. Papapoulos, Orhan Sezer, (unknown), Jean‐Yves Reginster	6
8	European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Newsletter 2007 ·SHILAP Revista de lepidopterología ·René Rizzoli, Nansa Burlet, David L. Cahall, Pierre D. Delmas, Erik Fink Eriksen, Dieter Felsenberg, John T. Grbic, Mats Jontell, Regina Landesberg, Andrea Laslop, (unknown), Socrates E. Papapoulos, Orhan Sezer, (unknown), Jean‐Yves Reginster	1
9	Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study 2007 ·Current Medical Research and Opinion ·Artur Racewicz, (unknown), David L. Cahall, Gary A. Cline, David E. Burgio	4
10	Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study 2005 ·Journal of Bone and Mineral Research ·Pierre D. Delmas, (unknown), Nelson B. Watts, Richard Eastell, Harry K. Genant, Andreas Grauer, David L. Cahall	417
11	Pasteurella multocida urinary tract infection 1983 ·Clinical Microbiology Newsletter ·(unknown), James R. Carlson, (unknown), David L. Cahall	8
12	Methicillin-resistant Staphylococcus aureus susceptibility testing with Abbott MS-2 system 1982 ·Antimicrobial Agents and Chemotherapy ·(unknown), (unknown), David L. Cahall	20
13	Influence of the interdigestive myoelectric complex on enteric flora in the rat 1982 ·Gastroenterology ·Larry D. Scott, David L. Cahall	70
14	Effect of herpes simplex virus infection on murine antibody-dependent cellular cytotoxicity and natural killer cytotoxicity 1981 ·Infection and Immunity ·Steve Kohl, M J Lawman, Barry T. Rouse, David L. Cahall	12
15	Murine Antibody-Dependent Cellular Cytotoxicity to Herpes Simplex Virus-Infected Target Cells 1979 ·The Journal of Immunology ·Steve Kohl, David L. Cahall, (unknown), (unknown)	48
16	Effect of rifampin on immunity to tuberculosis and on delayed hypersensitivity to purified protein derivative 1976 ·Infection and Immunity ·Anne S. Youmans, Guy P. Youmans, David L. Cahall	4
17	Macrophage migration inhibitory activity of mycobacterial growth inhibitory factor and the effect of a number of factors on mycobacterial growth inhibitory factor activity 1975 ·Infection and Immunity ·David L. Cahall, Guy P. Youmans	5
18	Conditions for production, and some characteristics, of mycobacterial growth inhibitory factor produced by spleen cells from mice immunized with viable cells of the attenuated H37Ra strain of Mycobacterium tuberculosis 1975 ·Infection and Immunity ·David L. Cahall, Guy P. Youmans	23
19	Molecular weight and other characteristics of mycobacterial growth inhibitory factor produced by spleen cells obtained from mice immunized with viable attenuated mycobacterial cells 1975 ·Infection and Immunity ·David L. Cahall, Guy P. Youmans	9
20	Employment of Tuberculostasis in Serum-Agar Medium for the Study of Production and Activity of Mycobactin 1971 ·Infection and Immunity ·Ivan Kochan, David L. Cahall, Carole A. Golden	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact